silicon-valley-biotech
(2)
Kriya Therapeutics, Inc.
Kriya Therapeutics is a clinical-stage biopharmaceutical company building one-time, AAV-based gene therapies for prevalent chronic diseases of high unmet need. Founded in 2019 and headquartered in Morrisville, North Carolina with operations in Silicon Valley, Kriya pairs a proprietary, vertically integrated manufacturing and R&D engine with a pipeline spanning ophthalmology, metabolic disease, and neurology. Its bet: gene therapy shouldn't be reserved for the rare few, but engineered and manufactured at the scale and cost needed to reach millions.
Retro Biosciences
Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.